Evidence map›Paper›PMID 34903732›Full record

ArticleSignal transduction and targeted therapy2021

Heterologous prime-boost with AdC68- and mRNA-based COVID-19 vaccines elicit potent immune responses in mice.

Wenjuan Li, Xingxing Li, Danhua Zhao, Jingjing Liu, Ling Wang, Miao Li, Xinyu Liu, Jia Li, Xiaohong Wu, Yuhua Li

Open access · goldAbstract readLetterComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Signal transduction and targeted therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Observational
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Wenjuan Li *Department of Arboviral Vaccine, National Institutes for Food and Drug Control, 102629, Beijing, China.
Xingxing Li *Department of Arboviral Vaccine, National Institutes for Food and Drug Control, 102629, Beijing, China.
Danhua Zhao *Department of Arboviral Vaccine, National Institutes for Food and Drug Control, 102629, Beijing, China.
Jingjing LiuDepartment of Arboviral Vaccine, National Institutes for Food and Drug Control, 102629, Beijing, China.
Ling WangDepartment of Arboviral Vaccine, National Institutes for Food and Drug Control, 102629, Beijing, China.
Miao LiDepartment of Arboviral Vaccine, National Institutes for Food and Drug Control, 102629, Beijing, China.
Xinyu LiuDepartment of Arboviral Vaccine, National Institutes for Food and Drug Control, 102629, Beijing, China.
Jia LiDepartment of Arboviral Vaccine, National Institutes for Food and Drug Control, 102629, Beijing, China.
Xiaohong WuDepartment of Arboviral Vaccine, National Institutes for Food and Drug Control, 102629, Beijing, China. wuxiaohong@nifdc.org.cn.
Yuhua LiDepartment of Arboviral Vaccine, National Institutes for Food and Drug Control, 102629, Beijing, China. liyuhua@nifdc.org.cn.
National Institutes for Food and Drug Control · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

COVID-19COVID-19 VaccinesAnimalsHumansImmunityMiceRNA, MessengerSARS-CoV-2COVID-19 VaccinesRNA, Messenger

Identifiers

PMID34903732
PMCPMC8666615
OpenAlexW4200547471

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.